Evidence map›Paper›PMID 20863721›Full record

Trial reportAcademic radiology2010

Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer.

Michael A Jacobs, Vered Stearns, Antonio C Wolff, Katarzyna Macura, Pedram Argani, Nagi Khouri, Theodore Tsangaris, Peter B Barker, Nancy E Davidson, Zaver M Bhujwalla and 2 more

Open access · greenAbstract readClinical Trial
In one paragraph

Trial report in Academic radiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Review
  8. European radiology experimental · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. In vivo Human MR Spectroscopy Using a Clinical Scanner: Development, Applications, and Future Prospects.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2022
    Review
  13. Article
  14. Journal of magnetic resonance imaging : JMRI · 2021
    Review
  15. Article
  16. HyperpolarizedRadiology. Imaging cancer · 2020
    Article
  17. Sodium Channel NaScientific reports · 2019
    Article
  18. Sodium homeostasis in the tumour microenvironment.Biochimica et biophysica acta. Reviews on cancer · 2019
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Michael A JacobsThe Russell H. Morgan Department of Radiology and Radiological Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. mikej@mri.jhu.edu
Vered Stearns
Antonio C Wolff
Katarzyna Macura
Pedram Argani
Nagi Khouri
Theodore Tsangaris
Peter B Barker
Nancy E Davidson
Zaver M Bhujwalla
David A Bluemke
Ronald Ouwerkerk
Johns Hopkins University · USSidney Kimmel Comprehensive Cancer Center · USJohns Hopkins Medicine · USNational Institutes of Health Clinical Center · US

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6M
Theranostic Imaging of Metastatic Prostate CancerP50CA103175 · NCI · JOHNS HOPKINS UNIVERSITY · PI AMBINDER, RICHARD FREDERICK · 2003 to 2015
$17.9M
PHASE I TRIALS OF ANTICANCER AGENTSU01CA070095 · NCI · JOHNS HOPKINS UNIVERSITY · PI CARDUCCI, MICHAEL A · 1995 to 2013
$8.6M
Molecular Biomedical Imaging Laboratory (NIBIB)ZIAEB000072 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI BLUEMKE, DAVID · 2010 to 2017
$5.0M
Proton MRSI of Human Breast Cancer at 3 and 7 TeslaR01CA125258 · NCI · JOHNS HOPKINS UNIVERSITY · PI BARKER, PETER B · 2007 to 2011
$1.9M
Multiparametric MRI characterization of breast tissueR01CA100184 · NCI · JOHNS HOPKINS UNIVERSITY · PI JACOBS, MICHAEL · 2004 to 2009
$1.4M
Molecular Biomedical Imaging Laboratory (CC)ZIACL090019 · CLC · CLINICAL CENTER · PI JONES, ELIZABETH C. · 2010 to 2017
$0k
Intramural NIH HHS ZIA CL090019Intramural NIH HHS ZIA EB000072NCI NIH HHS 5P30CA06973NCI NIH HHS P50CA103175NCI NIH HHS R01 CA100184NCI NIH HHS R01CA100184NCI NIH HHS R01CA125258NCI NIH HHS U01CA070095
6 · The paper itself

Abstract

RATIONALE AND

objectivesThe aim of this prospective study was to investigate using multiparametric and multinuclear magnetic resonance imaging during preoperative systemic therapy for locally advanced breast cancer. MATERIALS AND

methodsWomen with operable stage 2 or 3 breast cancer who received preoperative systemic therapy were studied using dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopy, and ²³Na magnetic resonance. Quantitative metrics of choline peak signal-to-noise ratio, total tissue sodium concentration, tumor volumes, and Response Evaluation Criteria in Solid Tumors were determined and compared to final pathologic results using receiver-operating characteristic analysis. Hormonal markers were investigated. Statistical significance was set at P < .05.

resultsEighteen eligible women were studied. Fifteen responded to therapy, four (22%) with pathologic complete response and 11 (61%) with pathologic partial response. Three patients (17%) had no response. Among estrogen receptor-positive, HER2-positive, and triple-negative phenotypes, observed frequencies of pathologic complete response, pathologic partial response, and no response were 2, 5, and 0; 1, 4, and 0; and 1, 1, and 3, respectively. Responders (pathologic complete response and pathologic partial response) had the largest reductions in choline signal-to-noise ratio (35%, from 7.2 ± 2.3 to 4.6 ± 2; P < .01) compared to nonresponders (11%, from 8.4 ± 2.7 to 7.5 ± 3.6; P = .13) after the first cycle. Total tissue sodium concentration significantly decreased in responders (27%, from 66 ± 18 to 48.4 ± 8 mmol/L; P = .01), while there was little change in nonresponders (51.7 ± 7.6 to 56.5 ± 1.6 mmol/L; P = .50). Lesion volume decreased in responders (40%, from 78 ± 78 to 46 ± 51 mm³; P = .01) and nonresponders (21%, from 100 ± 104 to 79.2 ± 87 mm³; P = .23) after the first cycle. The largest reduction in Response Evaluation Criteria in Solid Tumors occurred after the first treatment in responders (18%, from 24.5 ± 20 to 20.2 ± 18 mm; P = .01), with a slight decrease in tumor diameter noted in nonresponders (17%, from 23 ± 19 to 19.2 ± 19.1 mm; P = .80).

conclusionsMultiparametric and multinuclear imaging parameters were significantly reduced after the first cycle of preoperative systemic therapy in responders, specifically, choline signal-to-noise ratio and sodium. These new surrogate radiologic biomarkers maybe able to predict and provide a platform for potential adaptive therapy in patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMagnetic Resonance ImagingAdolescentAdultAgedAged, 80 and overBreast NeoplasmsFemaleHumansMiddle AgedNeoplasm StagingProspective StudiesRadiographySodiumSodium

Identifiers

PMID20863721
PMCPMC3401079
OpenAlexW2003692956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.